Clinical case: Nivolumab in 3rd line treatment of gastric cancer
Authors:
- 21 January 2026
- journal article
- Published by Alfmed LLC in Medical alphabet
- No. 33
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Рак желудкаMalignant tumours, 2024
- Early-onset gasrtric cancer (review)Siberian journal of oncology, 2024
- Evolution of drug therapy in patients with resectable gastric and esophageal‑gastric junction cancerResearch and Practical Medicine Journal, 2023
- Gastric cancer treatment: recent progress and future perspectivesJournal of Hematology & Oncology, 2023
- Immunotherapy in Gastric CancerCurrent Oncology, 2022
- Current treatment and recent progress in gastric cancerCA: A Cancer Journal for Clinicians, 2021
- Immunotherapy in advanced gastric cancer, is it the future?Critical Reviews in Oncology/Hematology, 2019
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric CancerJournal of Clinical Oncology, 2018